Molecular Target Approaches in Head and Neck Cancer: Epidermal Growth Factor Receptor and Beyond

Seminars in Radiation Oncology

Volumn 19, Issue 1, 2009, Pages 63-68

  Harari, Paul M ^a   Wheeler, Deric L ^a   Grandis, Jennifer R ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; LAPATINIB; PANITUMUMAB; TRASTUZUMAB; VANDETANIB;

CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CARCINOMA; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HEAD AND NECK NEOPLASMS; HUMANS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 56349163790     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semradonc.2008.09.009     Document Type: Review

References (62)

1. Grandis J.R., Chakraborty A., and Zeng Q. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J Cell Biochem 69 (1998) 55-62
2. Grandis J.R., Chakraborty A., and Melhem M.F. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 15 (1997) 409-416
3. Grandis J.R., Tweardy D.J., and Melhem M.F. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4 (1998) 13-20
4. Grandis J.R., and Sok J.C. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102 (2004) 37-46
5. Egloff A.M., and Grandis J. Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma. Expert Opin Ther Targets 10 (2006) 639-647
6. Grandis J.R., Melhem M.F., and Gooding W.E. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
7. Ang K.K., Berkey B.A., and Tu X. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
8. Chung C.H., Ely K., and McGavran L. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 24 (2006) 4170-4176
9. Grandis J.R., Zeng Q., and Tweardy D.J. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nat Med 2 (1996) 237-240
10. Rubin Grandis J., Tweardy D.J., and Melhem M.F. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 4 (1998) 13-20
11. Lui V.W., and Grandis J.R. EGFR-mediated cell cycle regulation. Anticancer Res 22 (2002) 1-11
12. Thomas S.M., and Grandis J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30 (2004) 255-268
13. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
14. Burtness B., Goldwasser M.A., and Flood W. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23 (2005) 8646-8654
15. Bonner J.A., Harari P.M., and Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
16. Soulieres D., Senzer N.N., and Vokes E.E. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
17. Agulnik M., Cohen E.W., and Cohen R.B. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25 (2007) 3978-3984
18. Siegfried J.M., Krishnamachary N., and Gaither D.A. Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer. Pulm Pharmacol Ther 12 (1999) 291-302
19. Gallo O., Franchi A., and Magnelli L. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3 (2001) 53-61
20. Masferrer J.L., Leahy K.M., and Koki A.T. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60 (2000) 1306-1311
21. Gschwind A., Prenzel N., and Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 62 (2002) 6329-6336
22. Klingmuller U., Wu H., and Hsiao J.G. Identification of a novel pathway important for proliferation and differentiation of primary erythroid progenitors. Proc Natl Acad Sci U S A 94 (1997) 3016-3021
23. Altorki N.K., Keresztes R.S., and Port J.L. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21 (2003) 2645-2650
24. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 (2006) 2666-2672
25. Temam S., Kawaguchi H., and El-Naggar A.K. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25 (2007) 2164-2170
26. Sugawa N., Ekstrand A.J., and James C.D. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 87 (1990) 8602-8606
27. Ekstrand A.J., James C.D., and Cavenee W.K. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51 (1991) 2164-2172
28. Huang H.S., Nagane M., and Klingbeil C.K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J Biol Chem 272 (1997) 2927-2935
29. Moscatello D.K., Montgomery R.B., and Sundareshan P. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13 (1996) 85-96
30. Scaltriti M., Rojo F., and Ocana A. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99 (2007) 628-638
31. Sok J.C., Coppelli F.M., and Thomas S.M. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006) 5064-5073
32. Mellinghoff I.K., Wang M.Y., and Vivanco I. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
33. Friedman H.S., and Bigner D.D. Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 353 (2005) 1997-1999
34. Learn C.A., Hartzell T.L., and Wikstrand C.J. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10 (2004) 3216-3224
35. Mizoguchi M., Betensky R.A., and Batchelor T.T. Activation of STAT3. MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol 65 (2006) 1181-1188
36. Johns T.G., Perera R.M., and Vernes S.C. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin Cancer Res 13 (2007) 1911-1925
37. Li B., Yuan M., and Kim I.A. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/Akt pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23 (2004) 4594-4602
38. Kuan C.T., Wikstrand C.J., and Archer G. Increased binding affinity enhances targeting of glioma xenografts by EGFRvIII-specific scFv. Int J Cancer 88 (2000) 962-969
39. Scott A.M., Lee F.T., and Tebbutt N. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A 104 (2007) 4071-4076
40. Ji H., Zhao X., and Yuza Y. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103 (2006) 7817-7822
41. Reid A., Vidal L., and Shaw H. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 43 (2007) 481-489
42. Sequist L.V., Bell D.W., and Lynch T.J. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007) 587-595
43. Riely G.J., Politi K.A., and Miller V.A. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin Cancer Res 12 (2006) 7232-7241
44. Arteaga C.L., and Baselga J. Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them?. Cancer Cell 5 (2004) 525-531
45. Engelman J.A., Zejnullahu K., and Mitsudomi T. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316 (2007) 1039-1043
46. Peruzzi B., and Bottaro D.P. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12 (2006) 3657-3660
47. Jo M., Stolz D.B., and Esplen J.E. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 275 (2000) 8806-8811
48. Mendelsohn J. Antibody-mediated EGF receptor blockade as an anticancer therapy: From the laboratory to the clinic. Cancer Immunol Immunother 52 (2003) 342-346
49. Sunada H., Magun B.E., and Mendelsohn J. Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci U S A 83 (1986) 3825-3829
50. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 (2005) 2445-2459
51. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33 (2006) 369-385
52. Bonner J.A., Harari P.M., and Giralt J. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
53. Cunningham D., Humblet Y., and Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004) 337-345
54. Van Cutsem E., Peeters M., and Siena S. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (2007) 1658-1664
55. Mukohara T., Engelman J.A., and Hanna N.H. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97 (2005) 1185-1194
56. Ciardiello F., Bianco R., and Caputo R. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10 (2004) 784-793
57. Viloria-Petit A., Crombet T., and Jothy S. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: A role for altered tumor angiogenesis. Cancer Res 61 (2001) 5090-5101
58. Wheeler D.L., Huang S., and Kruser T.J. Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 27 (2008) 3944-3956
59. Sergina N.V., Rausch M., and Wang D. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
60. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 18 (2004) 1926-1945
61. Allen G.W., Saba C., and Armstrong E.A. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67 (2007) 1155-1162
62. Reiter R., Gais P., and Jutting U. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 12 (2006) 5136-5141